

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**三生制药**  
**3SBIO INC.**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 1530)**

**VOLUNTARY ANNOUNCEMENT**  
**SUNSHINE MANDI HAS ENTERED INTO**  
**A COOPERATION AGREEMENT WITH**  
**HYBIO PHARMACEUTICAL IN RESPECT OF**  
**SEMAGLUTIDE INJECTION**

Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. (“**Sunshine Mandi**”), a wholly-owned subsidiary of Shenyang Sunshine Pharmaceutical Co., Ltd., which is in turn a subsidiary of 3SBio Inc. (the “**Company**”), entered into the Semaglutide Injection Cooperation Agreement (the “**Agreement**”) with Hybio Pharmaceutical Co., Ltd. (“**Hybio Pharmaceutical**”). Pursuant to the Agreement, Hybio Pharmaceutical and Sunshine Mandi will jointly develop, and supply/purchase on an exclusive basis, the Semaglutide Injection in weight management indication (“**Semaglutide WM**”) and share the profits from its sales. Sunshine Mandi will pay Hybio Pharmaceutical milestone payments of up to RMB270 million under the Agreement, including a consideration for preclinical technical results of RMB45 million, in addition to an exclusive purchase price and royalties. Sunshine Mandi will obtain the preclinical technical research results of the cooperation product from Hybio Pharmaceutical and entrust it with provision of clinical research and registration application in order to be the marketing authorization holder (MAH) of Semaglutide WM in certain regions, acquire the right to market the product exclusively and be responsible for the commercialization of the product in the region; meanwhile, Sunshine Mandi will entrust Hybio Pharmaceutical to be responsible for the exclusive production and supply of Semaglutide WM; after the launch of the product, Sunshine Mandi will pay Hybio Pharmaceutical two-digit royalties based on the gross profit derived from the net sales of the product in the region in each calendar year.

This is a voluntary announcement made by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**3SBio Inc.**  
**Dr. LOU Jing**  
*Chairman*

Shenzhen, the PRC  
28 May 2024

*As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Mr. HUANG Bin as non-executive Director; and Mr. PU Tianruo, Ms. YANG Hoi Ti Heidi, Mr. NG, Joo Yeow Gerry and Dr. ZHANG Dan as independent non-executive Directors.*